Lilly’s EBGLYSS gains FDA approval for patients aged 12 and older
The FDA's decision was influenced by data from the ADvocate 1, ADvocate 2 and ADhere clinical trials.
EMIS Inform WP
Left in limbo: When pharma halts rare disease research
UK’s pharma sector votes for post-Brexit clarity under new government
Embracing digital solutions for enhanced patient care
Novavax seeks FDA approval for updated Covid-19 vaccine
BIOSECURE Act could impact US biopharma drugs with half in clinical-stage development
Top ten late-breaking data to look for at ASCO 2024
Takeda tackles $900m restructuring plan after generics hurt annual profits
